The University of Chicago Header Logo

Connection

Scott Eggener to Humans

Back to Details
This is a "connection" page, showing publications Scott Eggener has written about Humans.
Scott Eggener
Connection Strength
2.990
Humans
  1. A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May; 213(5):590-599.
    View in: PubMed
    Score: 0.030
  2. Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2025 Feb; 135(2):339-345.
    View in: PubMed
    Score: 0.029
  3. Overcoming the Code Duello: Achieving Long-term Cure and Optimizing Quality of Life in Testicular Cancer. Eur Urol Focus. 2024 May; 10(3):355-356.
    View in: PubMed
    Score: 0.028
  4. Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jul; 86(1):1-3.
    View in: PubMed
    Score: 0.027
  5. Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
    View in: PubMed
    Score: 0.027
  6. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.
    View in: PubMed
    Score: 0.027
  7. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
    View in: PubMed
    Score: 0.026
  8. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. 2023 11; 9(6):966-973.
    View in: PubMed
    Score: 0.026
  9. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45.
    View in: PubMed
    Score: 0.026
  10. Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm. Eur Urol. 2023 04; 83(4):304-306.
    View in: PubMed
    Score: 0.025
  11. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 01; 209(1):49-57.
    View in: PubMed
    Score: 0.025
  12. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160.
    View in: PubMed
    Score: 0.025
  13. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114.
    View in: PubMed
    Score: 0.024
  14. Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative? Eur Urol. 2022 08; 82(2):161-162.
    View in: PubMed
    Score: 0.024
  15. Prostate Cancer, Decisional Regret and Exercise. J Urol. 2022 05; 207(5):952-953.
    View in: PubMed
    Score: 0.024
  16. Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 02; 81(2):218.
    View in: PubMed
    Score: 0.023
  17. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.
    View in: PubMed
    Score: 0.023
  18. How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137.
    View in: PubMed
    Score: 0.022
  19. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022 Jan; 40(1):15-19.
    View in: PubMed
    Score: 0.022
  20. Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Eur Urol. 2021 04; 79(4):552-553.
    View in: PubMed
    Score: 0.022
  21. Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142.
    View in: PubMed
    Score: 0.022
  22. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.021
  23. Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. Eur Urol. 2020 08; 78(2):161-162.
    View in: PubMed
    Score: 0.021
  24. Editorial Comment. J Urol. 2020 08; 204(2):287.
    View in: PubMed
    Score: 0.021
  25. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
    View in: PubMed
    Score: 0.021
  26. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343.
    View in: PubMed
    Score: 0.021
  27. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
    View in: PubMed
    Score: 0.020
  28. Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer. 2020 02 01; 126(3):470-472.
    View in: PubMed
    Score: 0.020
  29. Editorial Comment. J Urol. 2019 11; 202(5):942-943.
    View in: PubMed
    Score: 0.020
  30. Editorial Comment. J Urol. 2019 08; 202(2):263.
    View in: PubMed
    Score: 0.020
  31. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.
    View in: PubMed
    Score: 0.020
  32. Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.
    View in: PubMed
    Score: 0.019
  33. Editorial Comment. J Urol. 2019 02; 201(2):266-267.
    View in: PubMed
    Score: 0.019
  34. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82.
    View in: PubMed
    Score: 0.019
  35. Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. Eur Urol. 2019 04; 75(4):635-636.
    View in: PubMed
    Score: 0.019
  36. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709.
    View in: PubMed
    Score: 0.019
  37. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
    View in: PubMed
    Score: 0.019
  38. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.
    View in: PubMed
    Score: 0.019
  39. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18.
    View in: PubMed
    Score: 0.019
  40. Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506.
    View in: PubMed
    Score: 0.018
  41. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183.
    View in: PubMed
    Score: 0.018
  42. Testicular Cancer: Epidemiology, Diagnosis, and Management. Med Clin North Am. 2018 Mar; 102(2):251-264.
    View in: PubMed
    Score: 0.018
  43. Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol. 2018 06; 73(6):897-898.
    View in: PubMed
    Score: 0.018
  44. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196.
    View in: PubMed
    Score: 0.018
  45. Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. Eur Urol Focus. 2017 12; 3(6):522-523.
    View in: PubMed
    Score: 0.018
  46. Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evid Based Med. 2017 12; 22(6):222.
    View in: PubMed
    Score: 0.018
  47. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609.
    View in: PubMed
    Score: 0.018
  48. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evid Based Med. 2017 10; 22(5):192.
    View in: PubMed
    Score: 0.017
  49. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.
    View in: PubMed
    Score: 0.017
  50. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.
    View in: PubMed
    Score: 0.017
  51. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838.
    View in: PubMed
    Score: 0.017
  52. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017 04 01; 28(4):899-902.
    View in: PubMed
    Score: 0.017
  53. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720.
    View in: PubMed
    Score: 0.017
  54. Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urol Oncol. 2017 07; 35(7):461.e1-461.e6.
    View in: PubMed
    Score: 0.017
  55. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460.
    View in: PubMed
    Score: 0.017
  56. Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. Eur Urol. 2017 04; 71(4):515-516.
    View in: PubMed
    Score: 0.016
  57. Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6.
    View in: PubMed
    Score: 0.016
  58. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689.
    View in: PubMed
    Score: 0.016
  59. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.
    View in: PubMed
    Score: 0.016
  60. Editorial Comment. J Urol. 2016 12; 196(6):1668-1669.
    View in: PubMed
    Score: 0.016
  61. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675.
    View in: PubMed
    Score: 0.016
  62. The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. J Endourol. 2016 09; 30(9):997-1003.
    View in: PubMed
    Score: 0.016
  63. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.
    View in: PubMed
    Score: 0.016
  64. Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3.
    View in: PubMed
    Score: 0.016
  65. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.
    View in: PubMed
    Score: 0.016
  66. National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389.
    View in: PubMed
    Score: 0.015
  67. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.
    View in: PubMed
    Score: 0.015
  68. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93.
    View in: PubMed
    Score: 0.015
  69. Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55.
    View in: PubMed
    Score: 0.015
  70. Prostate Cancer Screening. JAMA. 2015 Aug 25; 314(8):825-6.
    View in: PubMed
    Score: 0.015
  71. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.
    View in: PubMed
    Score: 0.015
  72. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23.
    View in: PubMed
    Score: 0.015
  73. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
    View in: PubMed
    Score: 0.015
  74. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.
    View in: PubMed
    Score: 0.015
  75. Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes. Urol Oncol. 2015 Apr; 33(4):163.e1-6.
    View in: PubMed
    Score: 0.015
  76. How active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7.
    View in: PubMed
    Score: 0.015
  77. Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. J Urol. 2015 Mar; 193(3):826-31.
    View in: PubMed
    Score: 0.015
  78. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7.
    View in: PubMed
    Score: 0.015
  79. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102.
    View in: PubMed
    Score: 0.014
  80. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005. Urol Oncol. 2014 Aug; 32(6):935-6.
    View in: PubMed
    Score: 0.014
  81. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7.
    View in: PubMed
    Score: 0.014
  82. Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302. Urol Oncol. 2014 Aug; 32(6):936.
    View in: PubMed
    Score: 0.014
  83. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31.
    View in: PubMed
    Score: 0.014
  84. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.
    View in: PubMed
    Score: 0.014
  85. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7.
    View in: PubMed
    Score: 0.014
  86. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40.
    View in: PubMed
    Score: 0.014
  87. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978. Urol Oncol. 2014 May; 32(4):513-4.
    View in: PubMed
    Score: 0.014
  88. Elastographic search for the (high-grade) tree in the (prostatic) forest. BJU Int. 2014 Apr; 113(4):514-5.
    View in: PubMed
    Score: 0.014
  89. Editorial comment. J Urol. 2014 Jul; 192(1):81.
    View in: PubMed
    Score: 0.014
  90. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
    View in: PubMed
    Score: 0.014
  91. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
    View in: PubMed
    Score: 0.014
  92. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7.
    View in: PubMed
    Score: 0.013
  93. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013 Nov; 112(7):925-9.
    View in: PubMed
    Score: 0.013
  94. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27.
    View in: PubMed
    Score: 0.013
  95. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.013
  96. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.
    View in: PubMed
    Score: 0.013
  97. Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol. 2012 Jun; 19(3):6292.
    View in: PubMed
    Score: 0.012
  98. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4.
    View in: PubMed
    Score: 0.012
  99. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012 Jun; 187(6):1978-83.
    View in: PubMed
    Score: 0.012
  100. Environmental toxicology of testicular cancer. Urol Oncol. 2012 Mar-Apr; 30(2):212-5.
    View in: PubMed
    Score: 0.012
  101. Hazard of prostate cancer specific mortality after radical prostatectomy. J Urol. 2012 Jan; 187(1):124-7.
    View in: PubMed
    Score: 0.012
  102. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):106-10.
    View in: PubMed
    Score: 0.012
  103. Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. Urol Oncol. 2011 Nov-Dec; 29(6):826-8.
    View in: PubMed
    Score: 0.012
  104. Focal therapy for clinically localized prostate cancer. Arch Esp Urol. 2011 Oct; 64(8):815-22.
    View in: PubMed
    Score: 0.012
  105. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9.
    View in: PubMed
    Score: 0.011
  106. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43.
    View in: PubMed
    Score: 0.011
  107. Editorial comment. J Urol. 2011 Apr; 185(4):1254-5.
    View in: PubMed
    Score: 0.011
  108. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75.
    View in: PubMed
    Score: 0.011
  109. Chronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8.
    View in: PubMed
    Score: 0.011
  110. Chronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy. J Urol. 2010 Nov; 184(5):1867-71.
    View in: PubMed
    Score: 0.011
  111. TNM staging for renal cell carcinoma: time for a new method. Eur Urol. 2010 Oct; 58(4):517-9; discussion 519-21.
    View in: PubMed
    Score: 0.011
  112. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64.
    View in: PubMed
    Score: 0.010
  113. Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'. Br J Cancer. 2009 Dec 15; 101(12):2057-8; author reply 2059.
    View in: PubMed
    Score: 0.010
  114. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75.
    View in: PubMed
    Score: 0.010
  115. Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9.
    View in: PubMed
    Score: 0.010
  116. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7.
    View in: PubMed
    Score: 0.010
  117. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44.
    View in: PubMed
    Score: 0.010
  118. Editorial comment on: Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol. 2009 Aug; 56(2):361-2.
    View in: PubMed
    Score: 0.010
  119. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009 May; 19(3):268-73.
    View in: PubMed
    Score: 0.010
  120. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83.
    View in: PubMed
    Score: 0.010
  121. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):472.
    View in: PubMed
    Score: 0.010
  122. The clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41.
    View in: PubMed
    Score: 0.010
  123. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009 Apr; 181(4):1635-41; discussion 1641.
    View in: PubMed
    Score: 0.010
  124. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.
    View in: PubMed
    Score: 0.010
  125. Editorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol. 2009 Apr; 55(4):900-1.
    View in: PubMed
    Score: 0.010
  126. Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009 Jan 15; 115(2):303-10.
    View in: PubMed
    Score: 0.010
  127. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal. 2008 Oct 03; 8:963-73.
    View in: PubMed
    Score: 0.009
  128. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878.
    View in: PubMed
    Score: 0.009
  129. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616.
    View in: PubMed
    Score: 0.009
  130. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun; 71(6):1016-9.
    View in: PubMed
    Score: 0.009
  131. Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation. Eur Urol. 2008 Jul; 54(1):4-7.
    View in: PubMed
    Score: 0.009
  132. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.009
  133. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1.
    View in: PubMed
    Score: 0.009
  134. Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007 Jun; 69(6):1128-33.
    View in: PubMed
    Score: 0.009
  135. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.
    View in: PubMed
    Score: 0.008
  136. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35.
    View in: PubMed
    Score: 0.008
  137. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403.
    View in: PubMed
    Score: 0.008
  138. NMP22 and surveillance for recurrent bladder cancer. JAMA. 2006 Jul 05; 296(1):45; author reply 45-6.
    View in: PubMed
    Score: 0.008
  139. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
    View in: PubMed
    Score: 0.008
  140. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006 Apr 01; 66(5):495-502.
    View in: PubMed
    Score: 0.008
  141. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol. 2005 Aug; 174(2):500-4.
    View in: PubMed
    Score: 0.008
  142. Magnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis. J Urol. 2005 May; 173(5):1745-9; discussion 1749-50.
    View in: PubMed
    Score: 0.007
  143. MXene and prostate cancer: is there promising news? Nanomedicine (Lond). 2025 05; 20(9):1001-1014.
    View in: PubMed
    Score: 0.007
  144. Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Sep; 214(3):272-279.
    View in: PubMed
    Score: 0.007
  145. Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691.
    View in: PubMed
    Score: 0.007
  146. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4).
    View in: PubMed
    Score: 0.007
  147. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
    View in: PubMed
    Score: 0.007
  148. New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review. Prostate Cancer Prostatic Dis. 2026 Mar; 29(1):12-27.
    View in: PubMed
    Score: 0.007
  149. When is prostate cancer really cancer? J Natl Cancer Inst. 2025 Mar 01; 117(3):402-405.
    View in: PubMed
    Score: 0.007
  150. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Nat Genet. 2025 Feb; 57(2):334-344.
    View in: PubMed
    Score: 0.007
  151. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758.
    View in: PubMed
    Score: 0.007
  152. Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156.
    View in: PubMed
    Score: 0.007
  153. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2025 Jul-Aug; 15(4):e350-e361.
    View in: PubMed
    Score: 0.007
  154. Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628.
    View in: PubMed
    Score: 0.007
  155. Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2025 Mar; 11(2):266-272.
    View in: PubMed
    Score: 0.007
  156. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816.
    View in: PubMed
    Score: 0.007
  157. Survival outcomes and molecular drivers of testicular cancer in hispanic men. Urol Oncol. 2024 09; 42(9):293.e1-293.e7.
    View in: PubMed
    Score: 0.007
  158. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 12 01; 108(12):2336-2350.
    View in: PubMed
    Score: 0.007
  159. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
    View in: PubMed
    Score: 0.007
  160. Bilateral pulmonary artery tumour emboli from renal carcinoma. Lancet Oncol. 2004 Mar; 5(3):173.
    View in: PubMed
    Score: 0.007
  161. Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.
    View in: PubMed
    Score: 0.007
  162. Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy. Fertil Steril. 2024 Jun; 121(6):1069-1071.
    View in: PubMed
    Score: 0.007
  163. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
    View in: PubMed
    Score: 0.007
  164. Renal tumors in young adults. J Urol. 2004 Jan; 171(1):106-10.
    View in: PubMed
    Score: 0.007
  165. Urolithiasis associated with topiramate. Int Braz J Urol. 2004 Jan-Feb; 30(1):29-30; discussion 30-1.
    View in: PubMed
    Score: 0.007
  166. Penile refracture: case report. J Trauma. 2003 Oct; 55(4):793-4.
    View in: PubMed
    Score: 0.007
  167. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 12 01; 41(34):5296-5305.
    View in: PubMed
    Score: 0.007
  168. A noninfectious source of renal gas: embolization. J Urol. 2003 Sep; 170(3):913.
    View in: PubMed
    Score: 0.007
  169. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.
    View in: PubMed
    Score: 0.007
  170. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63.
    View in: PubMed
    Score: 0.006
  171. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53.
    View in: PubMed
    Score: 0.006
  172. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.
    View in: PubMed
    Score: 0.006
  173. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.
    View in: PubMed
    Score: 0.006
  174. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14.
    View in: PubMed
    Score: 0.006
  175. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.
    View in: PubMed
    Score: 0.006
  176. Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups. BMC Urol. 2022 Jul 18; 22(1):107.
    View in: PubMed
    Score: 0.006
  177. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022 09; 25(3):444-452.
    View in: PubMed
    Score: 0.006
  178. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol. 2022 07; 208(1):26-33.
    View in: PubMed
    Score: 0.006
  179. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022 07; 208(1):10-18.
    View in: PubMed
    Score: 0.006
  180. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25.
    View in: PubMed
    Score: 0.006
  181. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351.
    View in: PubMed
    Score: 0.006
  182. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512.
    View in: PubMed
    Score: 0.006
  183. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
    View in: PubMed
    Score: 0.006
  184. Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series. Urol Oncol. 2022 02; 40(2):18-24.
    View in: PubMed
    Score: 0.006
  185. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
    View in: PubMed
    Score: 0.006
  186. Bladder lipoma. J Urol. 2001 Oct; 166(4):1395.
    View in: PubMed
    Score: 0.006
  187. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
    View in: PubMed
    Score: 0.006
  188. Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Can J Urol. 2021 04; 28(2):10620-10624.
    View in: PubMed
    Score: 0.006
  189. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.
    View in: PubMed
    Score: 0.005
  190. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474.
    View in: PubMed
    Score: 0.005
  191. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483.
    View in: PubMed
    Score: 0.005
  192. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.
    View in: PubMed
    Score: 0.005
  193. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
    View in: PubMed
    Score: 0.005
  194. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.005
  195. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712.
    View in: PubMed
    Score: 0.005
  196. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
    View in: PubMed
    Score: 0.005
  197. Reply by Authors. J Urol. 2019 11; 202(5):958.
    View in: PubMed
    Score: 0.005
  198. Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611.
    View in: PubMed
    Score: 0.005
  199. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.
    View in: PubMed
    Score: 0.005
  200. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.005
  201. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281.
    View in: PubMed
    Score: 0.005
  202. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206.
    View in: PubMed
    Score: 0.005
  203. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272.
    View in: PubMed
    Score: 0.005
  204. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692.
    View in: PubMed
    Score: 0.005
  205. Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974.
    View in: PubMed
    Score: 0.005
  206. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.005
  207. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138.
    View in: PubMed
    Score: 0.005
  208. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.005
  209. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.
    View in: PubMed
    Score: 0.005
  210. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153.
    View in: PubMed
    Score: 0.005
  211. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.
    View in: PubMed
    Score: 0.005
  212. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.005
  213. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810.
    View in: PubMed
    Score: 0.005
  214. Region-specific microRNA signatures in the human epididymis. Asian J Androl. 2018 Nov-Dec; 20(6):539-544.
    View in: PubMed
    Score: 0.005
  215. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.005
  216. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.005
  217. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018 09 01; 24(9):433-443.
    View in: PubMed
    Score: 0.005
  218. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
    View in: PubMed
    Score: 0.005
  219. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019 Mar; 37(3):409-418.
    View in: PubMed
    Score: 0.005
  220. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
    View in: PubMed
    Score: 0.005
  221. No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology. 2018 Jul; 117:31-35.
    View in: PubMed
    Score: 0.005
  222. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10; 378(19):1767-1777.
    View in: PubMed
    Score: 0.005
  223. Region-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78.
    View in: PubMed
    Score: 0.004
  224. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517.
    View in: PubMed
    Score: 0.004
  225. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.
    View in: PubMed
    Score: 0.004
  226. Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. JSLS. 2017 Oct-Dec; 21(4).
    View in: PubMed
    Score: 0.004
  227. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.
    View in: PubMed
    Score: 0.004
  228. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.
    View in: PubMed
    Score: 0.004
  229. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497.
    View in: PubMed
    Score: 0.004
  230. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349.
    View in: PubMed
    Score: 0.004
  231. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20; 35(6):668-680.
    View in: PubMed
    Score: 0.004
  232. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6.
    View in: PubMed
    Score: 0.004
  233. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 01; 71(1):17-34.
    View in: PubMed
    Score: 0.004
  234. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397.
    View in: PubMed
    Score: 0.004
  235. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618.
    View in: PubMed
    Score: 0.004
  236. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct; 34(10):1373-82.
    View in: PubMed
    Score: 0.004
  237. HNF1 regulates critical processes in the human epididymis epithelium. Mol Cell Endocrinol. 2016 Apr 15; 425:94-102.
    View in: PubMed
    Score: 0.004
  238. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185.
    View in: PubMed
    Score: 0.004
  239. The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol. 2016 Feb; 13(2):91-8.
    View in: PubMed
    Score: 0.004
  240. Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Mol Hum Reprod. 2016 Feb; 22(2):69-82.
    View in: PubMed
    Score: 0.004
  241. Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22.
    View in: PubMed
    Score: 0.004
  242. Giant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5.
    View in: PubMed
    Score: 0.004
  243. The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74.
    View in: PubMed
    Score: 0.004
  244. Corneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance. Anesthesiology. 2015 May; 122(5):994-1001.
    View in: PubMed
    Score: 0.004
  245. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44.
    View in: PubMed
    Score: 0.004
  246. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94.
    View in: PubMed
    Score: 0.004
  247. Characterization of primary cultures of adult human epididymis epithelial cells. Fertil Steril. 2015 Mar; 103(3):647-54.e1.
    View in: PubMed
    Score: 0.004
  248. Preoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology. 2014 Dec; 84(6):1402-6.
    View in: PubMed
    Score: 0.004
  249. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr; 67(4):771-7.
    View in: PubMed
    Score: 0.004
  250. The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol. 2014 Nov; 28(11):1338-44.
    View in: PubMed
    Score: 0.004
  251. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
    View in: PubMed
    Score: 0.004
  252. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
    View in: PubMed
    Score: 0.004
  253. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8.
    View in: PubMed
    Score: 0.004
  254. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67.
    View in: PubMed
    Score: 0.003
  255. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.
    View in: PubMed
    Score: 0.003
  256. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.003
  257. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 2014 Apr 14; 25(4):455-68.
    View in: PubMed
    Score: 0.003
  258. Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53.
    View in: PubMed
    Score: 0.003
  259. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71.
    View in: PubMed
    Score: 0.003
  260. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83.
    View in: PubMed
    Score: 0.003
  261. The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200.
    View in: PubMed
    Score: 0.003
  262. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.003
  263. Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71.
    View in: PubMed
    Score: 0.003
  264. Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. BJU Int. 2014 Apr; 113(4):592-7.
    View in: PubMed
    Score: 0.003
  265. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15; 119(22):3992-4002.
    View in: PubMed
    Score: 0.003
  266. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014 Apr; 65(4):675-80.
    View in: PubMed
    Score: 0.003
  267. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52.
    View in: PubMed
    Score: 0.003
  268. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806.
    View in: PubMed
    Score: 0.003
  269. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96.
    View in: PubMed
    Score: 0.003
  270. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53.
    View in: PubMed
    Score: 0.003
  271. The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol. 2013 Aug; 31(4):977-82.
    View in: PubMed
    Score: 0.003
  272. Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.
    View in: PubMed
    Score: 0.003
  273. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.003
  274. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012 May-Jun; 32(3):819-37.
    View in: PubMed
    Score: 0.003
  275. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8.
    View in: PubMed
    Score: 0.003
  276. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73.
    View in: PubMed
    Score: 0.003
  277. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. 2012 Apr; 26(4):398-402.
    View in: PubMed
    Score: 0.003
  278. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.003
  279. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.
    View in: PubMed
    Score: 0.003
  280. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013 Aug; 31(6):904-8.
    View in: PubMed
    Score: 0.003
  281. Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41.
    View in: PubMed
    Score: 0.003
  282. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5.
    View in: PubMed
    Score: 0.003
  283. Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703.
    View in: PubMed
    Score: 0.003
  284. Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol. 2010 Nov; 184(5):1872-6.
    View in: PubMed
    Score: 0.003
  285. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73.
    View in: PubMed
    Score: 0.003
  286. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8.
    View in: PubMed
    Score: 0.003
  287. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
    View in: PubMed
    Score: 0.003
  288. Orthotopic neobladder versus Indiana pouch in women: a comparison of health related quality of life outcomes. J Urol. 2010 Jan; 183(1):201-6.
    View in: PubMed
    Score: 0.003
  289. Laparoscopic partial nephrectomy: a single-center evolving experience. Urology. 2010 Feb; 75(2):282-7.
    View in: PubMed
    Score: 0.003
  290. Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons. J Urol. 2009 Sep; 182(3):1126-32.
    View in: PubMed
    Score: 0.002
  291. Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia. J Urol. 2009 Sep; 182(3):860-5.
    View in: PubMed
    Score: 0.002
  292. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009 Aug; 175(2):882-90.
    View in: PubMed
    Score: 0.002
  293. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009 Feb; 73(2):316-22.
    View in: PubMed
    Score: 0.002
  294. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.
    View in: PubMed
    Score: 0.002
  295. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40.
    View in: PubMed
    Score: 0.002
  296. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8.
    View in: PubMed
    Score: 0.002
  297. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008 Jul 01; 113(1):84-96.
    View in: PubMed
    Score: 0.002
  298. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
    View in: PubMed
    Score: 0.002
  299. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28.
    View in: PubMed
    Score: 0.002
  300. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
    View in: PubMed
    Score: 0.002
  301. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
    View in: PubMed
    Score: 0.002
  302. Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug; 9(8):643-51.
    View in: PubMed
    Score: 0.002
  303. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8.
    View in: PubMed
    Score: 0.002
  304. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499.
    View in: PubMed
    Score: 0.002
  305. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006 Nov; 68(5):988-92.
    View in: PubMed
    Score: 0.002
  306. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71.
    View in: PubMed
    Score: 0.002
  307. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007 Apr; 51(4):940-7; discussion 947-8.
    View in: PubMed
    Score: 0.002
  308. Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. J Urol. 2006 Oct; 176(4 Pt 1):1339-43; discussion 1343.
    View in: PubMed
    Score: 0.002
  309. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol. 2006 Aug; 176(2):482-5.
    View in: PubMed
    Score: 0.002
  310. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157.
    View in: PubMed
    Score: 0.002
  311. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60.
    View in: PubMed
    Score: 0.002
  312. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11.
    View in: PubMed
    Score: 0.002
  313. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004 Dec; 172(6 Pt 1):2227-31.
    View in: PubMed
    Score: 0.002
  314. Plasma cell infiltration of the urinary bladder. Urology. 2004 Jul; 64(1):156-7.
    View in: PubMed
    Score: 0.002
  315. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28.
    View in: PubMed
    Score: 0.002
  316. The etiology of urolithiasis in HIV infected patients. J Urol. 2003 Feb; 169(2):475-7.
    View in: PubMed
    Score: 0.002
  317. Occlusion of an intraluminal endovascular stent graft after treatment of a ureteral-iliac artery fistula. Urology. 2002 Nov; 60(5):912.
    View in: PubMed
    Score: 0.002
  318. Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697.
    View in: PubMed
    Score: 0.002
  319. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar; 167(3):1469-74.
    View in: PubMed
    Score: 0.001
  320. Irritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis. Urology. 2002 Mar; 59(3):444.
    View in: PubMed
    Score: 0.001
  321. Anatomy of the rectourethralis muscle. Eur Urol. 2002 Jan; 41(1):94-100.
    View in: PubMed
    Score: 0.001
  322. Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol. 1994 Oct 15; 480 ( Pt 2):361-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.